Oral Contraceptive Use and Invasive Cervical Cancer by PARAZZINI, FABIO et al.
International Journal of Epidemiology
©International Epidemiological Association 1990
Vol. 19, No. 2
Printed in Great Britain
Oral Contraceptive Use and Invasive
Cervical Cancer
FABIO PARAZZJNI,* CARLO LA VECCHIA,*••• EVA NEGRI* AND RENATO NIAGGIt
Parazzini F (Mario Negri Institute for Pharmacological Research, 20157 Milan, Italy), La Vecchia C, Negri E and Maggi R.
Oral contraceptive use and invasive cervical cancer. InternationalJoumal of Epidemiology 1990; 19: 259-263.
The relationship between oral contraceptive use and the risk of invasive cervical cancer was investigated using data
from a hospital-based case-control study conducted in the greater Milan area. Northern Italy. A total of 367 women
under 60 years of age with a histologically confirmed diagnosis of invasive cervical cancer was compared with a group
of 323 controls admitted for a spectrum of acute conditions, non-gynaecological, hormonal or neoplastic and
apparently unrelated to oral contraceptive use. Cases had used oral contraceptives more frequently than controls, the
age-adjusted relative risk (RR) being 1.53 (95% confidence interval 0.99-2.36). The risk increased with duration of use:
compared with never users the age-adjusted RR was 1.48 for up to two years and 1.83 for more than two years (x? -
5.28, p - 0.02). Allowing for major identified potential confounding factors, including sexual and reproductive habits,
by means of multiple logistic regression, did not explain the associaton (multivariate RR 1.85 for ever use, 1.05 for up to
two years and 2.47 for more than two years). When the interaction between oral contraceptive use and parity or sexual
habits was analysed, the effects of various factors appeared independent: the point estimate for multiparous oral
contraceptive users versus nulliparous never users was 8.01. There was no consistent influence on risk of invasive
cervical cancer of age at first use, whereas the RRs were slightly greater for women who had first used oral
contraceptives less than ten years before or had last used them less than five years before diagnosis: these findings,
however, were far from significant.
A large number of investigations, including those
based on cytology screening programmes, cohort and
case-control studies have suggested that the incidence
of cervical neoplasms is higher in women who have
used oral contraceptives (OC). The estimated relative
risks, however, were only moderately increased, and
most studies could not adequately allow for major risk
factors for cervical neoplasia, chiefly indicators of sex-
ual habits.'"3
Several studies have focused on pre-invasive
abnormalities4"10 which are particularly prone to iden-
tification and classification bias, whereas the evidence
from studies of invasive cancer is still inconsistent. '2 A
cohort study from Britain" as well as two case-control
studies (one from US12 and one from eight different
countries13) have shown significantly elevated risks
among long-term oral contraceptive users, but no
noticeable association emerged from other studies
conducted in the US14 and Central America.13
To provide further information on the issue, we
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present here the updated results from a case-control
study conducted in Northern Italy. The availability of
information on major recognized risk factors for cervi-
cal cancer permitted careful examination of their con-
founding, modifying effects and interactions.
SUBJECTS AND METHODS
Since 1981 we have conducted a case-control study of
cervical neoplasia. The design of this investigation has
already been described.16" Briefly, trained interview-
ers identified subjects from hospital logs and clinical
records and questioned cases and controls using a stan-
dard questionnaire.
Information was obtained on personal character-
istics and habits, gynaecological and obstetric data,
related medical history, general indicators of sexual
habits (age at first intercourse, total number of sexual
partners), and a detailed history of lifetime use of oral
contraceptives and other female hormones. Despite
the rather sensitive nature of the interview, less than
2% of cases and controls refused to be interviewed,
reflecting a particularly favourable attitude towards
epidemiological data collection among patients in
Italy.
Cases were women younger than 60 years with a
histologically confirmed diagnosis of invasive cervical
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cancer (367 subjects: median age 47 years, range 22-
59) made in the year prior to interview, admitted to the
Obstetrics and Gyneacology Clinics of the University
of Milan, to the National Cancer Institute and the
'Ospedale Maggiore' of Milan (including the four
largest teaching and general hospitals in Milan).
Controls were patients admitted for acute conditions
to the 'Ospedale Maggiore' in Milan and several
specialized University Clinics. Women were not
included if they had been admitted for gynaecological,
hormonal or neoplastic disease or had undergone hys-
terectomy. A total of 323 controls aged 20-59 (median
age 47 years) were included in the analysis; of these,
25% were admitted for traumatic conditions (mostly
fractures and sprains), 28% for non-traumatic ortho-
paedic disorders (mostly low back pain and disc dis-
orders), 20% for surgical conditions (mostly
abdominal, such as appendicitis or strangulated her-
nia), and 27% for other illnesses such as ear, nose,
throat and dental disorders. They were blind for the
purpose and goals of the study (specifically the relation
between OC use and cervical cancer).
The current report is based on data obtained before
December 1987.
Data Analysis
We computed the relative risks (RR) of invasive cervi-
cal cancer, together with their 95% confidence inter-
vals (CI),18 from data stratified for quinquennia of age
by the Mantel-Haenszel procedure." When a factor
could be classified in more than two levels, the signif-
icance of the linear trend was assessed by the Mantel
test.20
In order to allow simultaneously for the effects of
several potential confounding factors, unconditional
logistic regression, with maximum likelihood fitting,21
was used. Included in the regression equations were
terms for age, marital status, education, parity,
number of sexual partners, age at first intercourse, cig-
arette smoking, history of Pap smears and use of bar-
rier contraceptive methods.
RESULTS
The distribution of cases and controls according to age,
socio-demographic indicators, parity, sexual habits,
lifetime frequency of Pap smears and use of barrier
contraceptive methods is presented in Table 1.
Women with invasive cervical cancer were more fre-
quently married, parous and less educated, had a
greater number of sexual partners, earlier age at first
intercourse, reported less frequent and less recent Pap
smears and less frequent use of barrier methods of
contraception.
The relation of various measures of OC use with
invasive cervical cancer is considered in Table 2. Cases
had used OC more frequently than controls, the age-
adjusted RR being 1.53. The risk increased with dura-
tion of use: compared with never users, the age-
adjusted RRs were 1.48 and 1.83 respectively for less
than two years and two years or more. This trend in
risk was statistically significant.
There was no consistent influence on risk of invasive
cervical cancer of age at first use, whereas the RRs
were slightly greater for women who had first used OC
less than ten years before diagnosis or had last used
them less than five years before diagnosis; these differ-
ences, however, were far from significant.
The multivariate RR values tended to be higher than
TABLE 1 Distribution of 367 cases of invasive cervical cancer and 323
controls' according to age and selected covariata.* Milan, Italy,
1981-87
Covariatcs
Age (years)
<40
40-49
50-59
Marital status
Never married
Ever married
Education (years)
<7
7-11
*12
Parity
0
1-2
Je3
Number of sexual
partners
0-1
» 2
unre ported
Age at first intercourse
(years)
<18
18-20
*21 or never
Number of Pap smears
0
»1
Time since last smear
<5 years
»5 or never
Use of barrier
contraceptive methods
Never used
Ever used
Cervical cancer
Number
86
117
164
28
339
263
72
32
28
181
158
271
91
5
70
139
158
241
126
80
287
344
23
%
23.4
31 9
44.7
7 6
92.4
71.7
19.6
8.7
7.6
49.3
43.1
73.8
24.8
1.4
19.1
37.9
43.1
65.7
34.3
21.8
78.2
93.7
6.3
Controls
Number
92
90
141
45
278
175
94
54
69
189
65
267
46
10
25
100
195
98
225
185
138
286
37
%
28.5
27.9
43.7
13.9
861
54.2
29.1
16.7
21.4
58.5
20.1
82.7
14.2
3.1
7.8
31.3
60.9
30.3
69.7
57.3
42.7
88.5
11.5
*In some cases the number of various strata do not add to the total
owing to a few missing values.
ORAL CONTRACEPTIVES AND CERVICAL CANCER 261
TABLE 2 Relative risk of invasive cervical cancer in relation to various
measures of oral contraceptive use. Milan, Italy, 1981-87
Ever use
No
Yes
Duration of use
(years)*
=£2
>2
Age at first use
(years)
<25
25-29
S=30
Time since first
use (years)
<10
S>10
Time since last
use (years)
<5
* 5
cancer
298
69
36
33
17
21
31
39
30
22
47
Controls
276
47
27
20
13
14
20
25
22
12
35
Relative risk estimates
(95% CI)
M-H*
It
1.53
(0.99-2.36)
1 48
(0.87-2.69)
1.83
(1.00-3 34)
1.49
(0.68-3.26)
1 72
(0.92-3.60)
1.43
(0.79-2.60)
1.86
(1.02-3 39)
1.28
(0.72-2.29)
2.06
(0.96-4 42)
1.47
(0.86-2.51)
M L R "
It
1.85
(1.00-3 14)
1.05
(0.84-3.24)
2.47
(1.19-5 13)
2.41
(0.98-5.93)
1.67
(0.74-3.77)
1 23
(0.62-2.44)
1.98
(1.01-3 89)
1 28
(0.67-2.45)
1.69
(0.78-3 68)
1.53
(0.86-2.73)
'Mantel-Haenszel estimates adjusted for age.
"Estimates from multiple logistic regression equations including
terms for age, marital status, education, parity, number of sexual
partners, age at first intercourse, cigarette smoking, history of Pap
smears and use of barrier methods of contraception.
tReference category.
fTest for trend age adjusted ^=5.28 p=0.02; multivariate x?~7.24
p-0.007.
the ones adjusted for age only. The point estimate for
ever use was 1.85, and 2.47 for more than two years,
both being statistically significant. The multivariate
risks in relation to age at first use tended to decrease
with later age. This, however, should be considered
within the context of the complex interaction between
various temporal factors (age, time since first and last
use).
The interaction between OC use and the other major
risk factors for cervical cancer in this study (ie parity
and number of sexual partners) is considered in Table
3. The RR for OC use was elevated in subsequent
strata of parity and number of sexual partners. Conse-
quently, the effect of the factors considered appeared
independent. Compared with never user nulliparous
women, the point estimate rose to 8.01 for OC users
with three births or more.
Finally, the relative risks were not significantly het-
erogeneous in various strata of age, socioeconomic
factors, parity, sexual habits, time since last Pap smear
and use of barrier methods of contraception, most of
the estimated values being above unity (Table 4).
DISCUSSION
According to these results, women who had used OCs
more frequently experienced invasive cervical cancer.
The risk increased with duration of use and was about
double in OC users for more than two years.
Diagnostic bias (OC users tend to be more fre-
quently screened by Pap smear and consequently more
easily diagnosed for cervical neoplasia) has been
claimed as a major problem in the interpretation of the
association between OCs and cervical pre-invasive
neoplasms.3 However, it is conceivable that if OC
users preferentially attended screening clinics, they
would be more likely to be diagnosed in an early stage
of the process of carcinogenesis, thus artificially low-
ering the frequency of OC users among invasive cases.
Likewise, separate analyses or simultaneously
allowing for lifetime Pap smear frequency, time from
last Pap and several other potential confounding fac-
tors (including socioeconomic status, sexual habits and
reproductive variables) did not show any appreciable
interaction or materially change the risk estimates.
Indeed the relative risks, if any, tended to increase
after multiple adjustment. Plausible explanation for
this finding is the effect of social class, which is inver-
sely related with invasive cervical cancer, but directly
with OC use in this population22 and the more frequent
use of screening by OC users.
Finally, selection bias should not influence these
TABLE 3 Interaction between parity, number of sexual partners and
oral contraceptive use of cervical cancer. Milan, Italy, 1981-87
Parity
0
1-2
S=3
Number of sexual
partners
0-1
2
» 3
Relative risks* (95% CI) for oral contraceptive use
Never
I t
2.42(1.44^.06)
5.66(3.26-9.80)
It
1.55(0.90-2.67)
2.52(1.26-5.05)
Ever
2.27 (0.60-8.58)
3.62(1.69-7.75)
8.01 (3.55-18.06)
1.20(0.72-1.99)
2.41 (0.78-7.45)
4.29(1.45-12.69)
*Mantel-Haenszel estimates adjusted for age.
tReference category.
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TABLE 4 Relative risk of invasive cervical cancer according to ever use
of oral contraceptives and selected covariates. Milan, Italy, 1981-87
Covariates
Age (years)
<40
40-49
50-59
Marital status
Never married
Ever married
Education (years)
<7
7-11
S12
Parity
0
1-2
3*3
Number of sexual partners
0-1
2
* 3
Age at first intercourse (years)
<18
18-20
S21 or never
Time since last Pap smear
<5 years
*5 years
Ever use of barrier contraceptive methods
Yes
No
Relative risk
estimates (95% Cl)*
1.49(0.80-2.79)
1.77(0.84-3.73)
3.04 (0.40-3 49)
0.78 (0 22-2.85)
1.54(0.97-2.44)
1.53 (0.84-2 78)
2.67(1.07-6.65)
1.06(0 36-3.06)
2.27(0.60-5.58)
1.24(0.68-2.27)
1.11 (0.47-2 62)
1.20(0.72-1.99)
2.29(0.49-10.59)
2.13(0.53-8.62)
1.10(0.33-3.60)
1.36(0.66-2 77)
1.28(0.63-2.61)
1.75 (0.89-3.47)
2.49(1.20-5.17)
1.04(0.29-3.73)
1.66(1.03-2.66)
•Mantel-Haenszel estimates adjusted for age.
results, since cases and controls were identified in insti-
tutions covering a broadly comparable catchment area
and, despite the sensitive nature of the interview, par-
ticipation in the study was almost complete.
Thus, the present study adds further evidence to the
hypothesis of a positive association between cervical
cancer and oral contraceptives. Although the evidence
is not totally consistent, the two largest studies, con-
ducted in the US'2 and eight different countries,13
reported an approximately 50% higher risk of invasive
cervical cancer among long-term OC users, which was
not explained by allowing for the potential effects of
major covariates, including indicators of sexual habits,
which were suspected to exert a major confounding
effect.
Interpretation of these findings in biological terms is
largely tentative. There is some suggestion in the pres-
ent as well as in previous work that the relative risk is
higher in the short term, and decreases with time since
first and last use. Within the framework of the multi-
stage theory of carcinogenesis this would suggest a
later stage effect, which is common to other hormonal-
related factors, for example the role of oestrogens in
endometrial carcinogenesis.23 This also agrees with the
observation that oral contraceptives may accelerate
the evolution of the pre-invasive condition to invasive
neoplasia.24
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